Clovis Oncology Announces $235.75 Million Offering of Common Stock

January 18, 2017

Willkie represents biopharmaceutical company Clovis Oncology, Inc. in its underwritten public offering of 5,750,000 shares of its common stock. 

Willkie client Clovis Oncology, Inc. (NASDAQ:CLVS) sold 5,750,000 shares of its common stock at $41.00 per share in an underwritten public offering. The offering is valued at $235.75 million. J. P. Morgan Securities LLC and BofA Merrill Lynch acted as joint book-running managers and Stifel and SunTrust Robinson Humphrey acted as co-managers for the offering. The offering closed on January 9, 2017.

Based in Boulder, CO, Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Willkie previously represented Clovis Oncology in its IPO, several subsequent equity offerings and a 144A offering of convertible senior notes. Willkie has also represented Clovis Oncology in numerous acquisitions and licensing deals of products and businesses.

The current transaction was handled by partner Thomas Mark and associate Neesha Mallavarapu. Partner Michael Brandt and associate Laura Acker also provided assistance.